278 related articles for article (PubMed ID: 15171718)
1. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
[TBL] [Abstract][Full Text] [Related]
2. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
3. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
4. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
5. Direct stimulation of cortisol secretion from the human NCI H295 adrenocortical cell line by vasoactive intestinal polypeptide.
Cobb VJ; Williams BC; Mason JI; Walker SW
J Hypertens; 1997 Dec; 15(12 Pt 2):1735-8. PubMed ID: 9488231
[TBL] [Abstract][Full Text] [Related]
6. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.
Yamada H; Watanabe M; Yada T
Regul Pept; 2004 Dec; 123(1-3):147-53. PubMed ID: 15518905
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
Lutz EM; Ronaldson E; Shaw P; Johnson MS; Holland PJ; Mitchell R
Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
[TBL] [Abstract][Full Text] [Related]
10. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
12. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
[TBL] [Abstract][Full Text] [Related]
14. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
[TBL] [Abstract][Full Text] [Related]
16. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
17. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
18. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
19. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
